Common features of chromatin in aging and cancer: Cause or coincidence?

Trends in Cell Biology

Volumn 24, Issue 11, 2014, Pages 686-694

  Zane, Linda ^a   Sharma, Vivek ^a   Misteli, Tom ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE; LONG UNTRANSLATED RNA; CHROMATIN;

CARCINOGENESIS; CELL AGING; CHROMATIN; DNA METHYLATION; HISTONE MODIFICATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; AGING; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM;

AGING; ANIMALS; CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; NEOPLASMS; RNA, LONG NONCODING;

EID: 84927698872     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.07.001     Document Type: Review

References (141)

1. de Graaf C.A., van Steensel B. Chromatin organization: form to function. Curr. Opin. Genet. Dev. 2013, 23:185-190.
2. Misteli T. The cell biology of genomes: bringing the double helix to life. Cell 2013, 152:1209-1212.
3. Tollefsbol T.O. Dietary epigenetics in cancer and aging. Cancer Treat. Res. 2014, 159:257-267.
4. Waldmann T., Schneider R. Targeting histone modifications - epigenetics in cancer. Curr. Opin. Cell Biol. 2013, 25:184-189.
5. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
6. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
7. Cruickshanks H.A., Adams P.D. Chromatin: a molecular interface between cancer and aging. Curr. Opin. Genet. Dev. 2011, 21:100-106.
8. Lopez-Otin C., et al. The hallmarks of aging. Cell 2013, 153:1194-1217.
9. Huidobro C., et al. Aging epigenetics: causes and consequences. Mol. Aspects Med. 2013, 34:765-781.
10. Putiri E.L., Robertson K.D. Epigenetic mechanisms and genome stability. Clin. Epigenetics 2011, 2:299-314.
11. Fraga M.F., et al. Cross-talk between aging and cancer: the epigenetic language. Ann. N. Y. Acad. Sci. 2007, 1100:60-74.
12. Deaton A.M., Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25:1010-1022.
13. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1:239-259.
14. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
15. Cruickshanks H.A., et al. Senescent cells harbour features of the cancer epigenome. Nat. Cell Biol. 2013, 15:1495-1506.
16. Fraga M.F., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci U.S.A. 2005, 102:10604-10609.
17. Jintaridth P., Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. Physiol. Genomics 2010, 41:194-200.
18. Lange N.E., et al. Alu and LINE-1 methylation and lung function in the Normative Aging Study. BMJ Open 2012, 2:e001231.
19. Rodriguez J., et al. Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells. Nucleic Acids Res. 2008, 36:770-784.
20. Christensen B.C., et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009, 5:e1000602.
21. Heyn H., et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10522-10527.
22. Zhu Z.Z., et al. Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. Cancer Causes Control 2011, 22:437-447.
23. Furniss C.S., et al. Line region hypomethylation is associated with lifestyle and differs by human papillomavirus status in head and neck squamous cell carcinomas. Cancer Epidemiol. Biomarkers Prev. 2008, 17:966-971.
24. Baba Y., et al. LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. Clin. Cancer Res. 2014, 20:1114-1124.
25. Aoki Y., et al. Correction: genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. Genome Med. 2013, 5:88.
26. Wilhelm C.S., et al. Implications of LINE1 methylation for bladder cancer risk in women. Clin. Cancer Res. 2010, 16:1682-1689.
27. Daskalos A., et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int. J. Cancer 2009, 124:81-87.
28. Chen R.Z., et al. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:89-93.
29. Gaudet F., et al. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
30. Sakatani T., et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005, 307:1976-1978.
31. Spruijt C.G., et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 2013, 152:1146-1159.
32. Thomson J.P., et al. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature 2010, 464:1082-1086.
33. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013, 14:R115.
34. Lujambio A., et al. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 2010, 29:6390-6401.
35. Issa J.P., et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 1994, 7:536-540.
36. Teschendorff A.E., et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010, 20:440-446.
37. McGarvey K.M., et al. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res. 2008, 68:5753-5759.
38. Easwaran H., et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 2012, 22:837-849.
39. Agrelo R., et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8822-8827.
40. Agrelo R., et al. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J. Clin. Oncol. 2005, 23:3940-3947.
41. Hoeijmakers J.H. DNA damage, aging, and cancer. N. Engl. J. Med. 2009, 361:1475-1485.
42. Casillas M.A., et al. Transcriptional control of the DNA methyltransferases is altered in aging and neoplastically-transformed human fibroblasts. Mol. Cell. Biochem. 2003, 252:33-43.
43. Lopatina N., et al. Differential maintenance and de novo methylating activity by three DNA methyltransferases in aging and immortalized fibroblasts. J. Cell. Biochem. 2002, 84:324-334.
44. Hermann A., et al. Biochemistry and biology of mammalian DNA methyltransferases. Cell. Mol. Life Sci. 2004, 61:2571-2587.
45. Eads C.A., et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999, 59:2302-2306.
46. Robertson K.D., et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999, 27:2291-2298.
47. Rothbart S.B., Strahl B.D. Interpreting the language of histone and DNA modifications. Biochim. Biophys. Acta 2014, 10.1016/j.bbagrm.2014.03.001.
48. Tan M., et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146:1016-1028.
49. Sandoval J., Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 2012, 22:50-55.
50. Dang W., et al. Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature 2009, 459:802-807.
51. Feser J., et al. Elevated histone expression promotes life span extension. Mol. Cell 2010, 39:724-735.
52. O'Sullivan R.J., et al. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat. Struct. Mol. Biol. 2010, 17:1218-1225.
53. Ivanov A., et al. Lysosome-mediated processing of chromatin in senescence. J. Cell Biol. 2013, 202:129-143.
54. Hu Z., et al. Nucleosome loss leads to global transcriptional up-regulation and genomic instability during yeast aging. Genes Dev. 2014, 28:396-408.
55. Fraga M.F., Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 2005, 4:1377-1381.
56. Shogren-Knaak M., et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006, 311:844-847.
57. Zhou B.R., et al. Histone H4 K16Q mutation, an acetylation mimic, causes structural disorder of its N-terminal basic patch in the nucleosome. J. Mol. Biol. 2012, 421:30-37.
58. Sharma G.G., et al. MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol. Cell. Biol. 2010, 30:3582-3595.
59. Li X., et al. MOF and H4 K16 acetylation play important roles in DNA damage repair by modulating recruitment of DNA damage repair protein Mdc1. Mol. Cell. Biol. 2010, 30:5335-5347.
60. Vempati R.K., Haldar D. DNA damage in the presence of chemical genotoxic agents induce acetylation of H3K56 and H4K16 but not H3K9 in mammalian cells. Mol. Biol. Rep. 2012, 39:303-308.
61. Vaquero A., et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 2004, 16:93-105.
62. Pruitt K., et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006, 2:e40.
63. Sinclair D.A., Guarente L. Extrachromosomal rDNA circles - a cause of aging in yeast. Cell 1997, 91:1033-1042.
64. Rogina B., Helfand S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15998-16003.
65. Tissenbaum H.A., Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
66. Herranz D., Serrano M. SIRT1: recent lessons from mouse models. Nat. Rev. Cancer 2010, 10:819-823.
67. Oberdoerffer P., et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008, 135:907-918.
68. Yuan H., et al. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther. 2013, 6:1399-1416.
69. Calvanese V., et al. The role of epigenetics in aging and age-related diseases. Ageing Res. Rev. 2009, 8:268-276.
70. Schotta G., et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 2004, 18:1251-1262.
71. Regha K., et al. Active and repressive chromatin are interspersed without spreading in an imprinted gene cluster in the mammalian genome. Mol. Cell 2007, 27:353-366.
72. Fraga M.F., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
73. Pogribny I.P., et al. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006, 27:1180-1186.
74. Tryndyak V.P., et al. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol. Ther. 2006, 5:65-70.
75. Jorgensen S., et al. Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res. 2013, 41:2797-2806.
76. Schotta G., et al. A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse. Genes Dev. 2008, 22:2048-2061.
77. Shumaker D.K., et al. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8703-8708.
78. Sarg B., et al. Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J. Biol. Chem. 2002, 277:39195-39201.
79. Chicas A., et al. H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:8971-8976.
80. Elsheikh S.E., et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009, 69:3802-3809.
81. Barlesi F., et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J. Clin. Oncol. 2007, 25:4358-4364.
82. Michishita E., et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008, 452:492-496.
83. Mostoslavsky R., et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124:315-329.
84. Kanfi Y., et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012, 483:218-221.
85. Liu Y., et al. Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. Protein Cell 2013, 4:702-710.
86. Kawahara T.L., et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009, 136:62-74.
87. Chandra T., et al. Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol. Cell 2012, 47:203-214.
88. Sadaie M., et al. Redistribution of the lamin B1 genomic binding profile affects rearrangement of heterochromatic domains and SAHF formation during senescence. Genes Dev. 2013, 27:1800-1808.
89. Muller-Tidow C., et al. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 2010, 116:3564-3571.
90. Xia R., et al. High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. Arch. Pathol. Lab. Med. 2013, 137:1761-1769.
91. Park Y.S., et al. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann. Surg. Oncol. 2008, 15:1968-1976.
92. Aplan P.D. Chromosomal translocations involving the MLL gene: molecular mechanisms. DNA Repair 2006, 5:1265-1272.
93. Greer E.L., et al. Members of the H3K4 trimethylation complex regulate lifespan in a germline-dependent manner in C. elegans. Nature 2010, 466:383-387.
94. Bernstein B.E., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
95. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 2006, 75:243-269.
96. Vastenhouw N.L., Schier A.F. Bivalent histone modifications in early embryogenesis. Curr. Opin. Cell Biol. 2012, 24:374-386.
97. Shah P.P., et al. Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes Dev. 2013, 27:1787-1799.
98. Hansen K.D., et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 2011, 43:768-775.
99. Bracken A.P., et al. The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007, 21:525-530.
100. Kleer C.G., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11606-11611.
101. Bachmann I.M., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24:268-273.
102. Bender S., et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 2013, 24:660-672.
103. Vire E., et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
104. Kondo Y., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
105. Burgess R.C., et al. DNA damage, chromatin, and transcription: the trinity of aging. Curr. Opin. Cell Biol. 2012, 24:724-730.
106. Castel S.E., Martienssen R.A. RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond. Nat. Rev. Genet. 2013, 14:100-112.
107. Rinn J.L., Chang H.Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 2012, 81:145-166.
108. Bertone P., et al. Global identification of human transcribed sequences with genome tiling arrays. Science 2004, 306:2242-2246.
109. Cabili M.N., et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011, 25:1915-1927.
110. Hangauer M.J., et al. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013, 9:e1003569.
111. Yoon J.H., et al. LincRNA-p21 suppresses target mRNA translation. Mol. Cell 2012, 47:648-655.
112. David R. RNA: a new layer of regulation. Nat. Rev. Mol. Cell Biol. 2011, 12:766.
113. Maass P.G., et al. Long non-coding RNA in health and disease. J. Mol. Med. (Berl.) 2014, 92:337-346.
114. Gupta R.A., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076.
115. Tsai M.C., et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329:689-693.
116. Quagliata L., et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 2014, 59:911-923.
117. Wang K.C., et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011, 472:120-124.
118. Takayama K., et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 2013, 32:1665-1680.
119. Beckedorff F.C., et al. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 2013, 9:e1003705.
120. Lee J.T., Bartolomei M.S. X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 2013, 152:1308-1323.
121. Yildirim E., et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 2013, 152:727-742.
122. Abdelmohsen K., et al. Senescence-associated lncRNAs: senescence-associated long noncoding RNAs. Aging Cell 2013, 12:890-900.
123. Kim W.Y., Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275.
124. Matheu A., et al. Anti-aging activity of the Ink4/Arf locus. Aging Cell 2009, 8:152-161.
125. INK4B tumor suppressor gene. Oncogene 2011, 30:1956-1962.
126. Yap K.L., et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell 2010, 38:662-674.
127. Yu W., et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451:202-206.
128. Pasmant E., et al. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011, 25:444-448.
129. Sharma V., Misteli T. Non-coding RNAs in DNA damage and repair. FEBS Lett. 2013, 587:1832-1839.
130. Wan G., et al. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell. Signal. 2013, 25:1086-1095.
131. Wan G., et al. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J. 2013, 32:2833-2847.
132. Scaffidi P., Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat. Cell Biol. 2011, 13:1051-1061.
133. Roukos V., et al. The cellular etiology of chromosome translocations. Curr. Opin. Cell Biol. 2013, 25:357-364.
134. Scaffidi P., Misteli T. Cancer epigenetics: from disruption of differentiation programs to the emergence of cancer stem cells. Cold Spring Harb. Symp. Quant. Biol. 2010, 75:251-258.
135. Goodarzi A.A., et al. The influence of heterochromatin on DNA double strand break repair: getting the strong, silent type to relax. DNA Repair 2010, 9:1273-1282.
136. Nagarajan R.P., et al. Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Res. 2014, 24:761-774.
137. Ellinger J., et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int. J. Cancer 2010, 127:2360-2366.
138. Manuyakorn A., et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J. Clin. Oncol. 2010, 28:1358-1365.
139. He L.R., et al. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 2009, 9:461.
140. Gibb E.A., et al. Human cancer long non-coding RNA transcriptomes. PLoS ONE 2011, 6:e25915.
141. Choe M.K., et al. Functional elements demarcated by histone modifications in breast cancer cells. Biochem. Biophys. Res. Commun. 2012, 418:475-482.